Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 5/20 | 0.71 |
| ▸ | GAA | P10253 | 6/20 | 0.56 |
| ▸ | NPC1 | O15118 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6029542 | 0.88 | KCNMA1 (0.84) | KCNMA1GAANPC1SMN1; SMN2TP53 | |
| SCHEMBL18027729 | 0.87 | KCNMA1 (0.71) | KCNMA1GAANPC1SMN1; SMN2TP53 | |
| SCHEMBL2605540 | 0.87 | KCNMA1 (0.82) | KCNMA1GAANPC1SMN1; SMN2TP53 | |
| SCHEMBL2605548 | 0.86 | KCNMA1 (0.82) | KCNMA1GAANPC1SMN1; SMN2TP53 | |
| SCHEMBL12548985 | 0.86 | KCNMA1 (0.66) | KCNMA1GAANPC1SMN1; SMN2TP53 | |
| SCHEMBL14363236 | 0.83 | KCNMA1 (0.77) | KCNMA1GAANPC1SMN1; SMN2TP53 | |
| SCHEMBL14363234 | 0.83 | KCNMA1 (0.72) | KCNMA1GAANPC1SMN1; SMN2TP53 | |
| SCHEMBL10873010 | 0.83 | KCNMA1 (1.00) | KCNMA1GAANPC1SMN1; SMN2TP53 | |
| SCHEMBL12937566 | 0.81 | KCNMA1 (0.73) | KCNMA1GAANPC1SMN1; SMN2TP53 | |
| SCHEMBL12690279 | 0.81 | KCNMA1 (0.72) | KCNMA1GAANPC1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450318-B2 | Method to treat infections using anti-infective agents | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2013-05-28 | — | — | US | disclosed |
| US-8450318-B2 | Method to treat infections using anti-infective agents | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2013-05-28 | — | — | US | disclosed |
| US-20110136840-A1 | ANTI-INFECTIVE AGENTS | MAZIK, MONIKA (DE) | 2011-06-09 | — | — | US | disclosed |
| US-20110136840-A1 | ANTI-INFECTIVE AGENTS | MAZIK, MONIKA (DE) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136840-A1 | ANTI-INFECTIVE AGENTS | ICAM1, MANBA, ALG1 | KCNMA1 4600/4885GAA 155/4885NPC1 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.